Anúncio
Anúncio

CRL

CRL logo

Charles River Laboratories International, Inc.

200.69
USD
Patrocinado
-1.29
-0.64%
31 de dez., 12:15 UTC -5
Abrir

Relatórios de Lucros CRL

Rácio de surpresa positiva

CRL separação 39 de 39 últimas estimativas.

100%

Próximo Relatório

Data do Próximo Relatório
17 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$997.78M
/
$2.36
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-0.70%
/
-2.88%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-0.48%
/
-11.28%

Charles River Laboratories International, Inc. earnings per share and revenue

On 05 de nov. de 2025, CRL reported earnings of 2.43 USD per share (EPS) for Q3 25, beating the estimate of 2.36 USD, resulting in a 2.88% surprise. Revenue reached 1.00 bilhão, compared to an expected 1.00 bilhão, with a 0.42% difference. The market reacted with a -5.71% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analistas forecast an EPS of 2.36 USD, with revenue projected to reach 997.78 milhão USD, implying an diminuir of -2.88% EPS, and diminuir of -0.70% in Revenue from the last quarter.
FAQ
For Q3 2025, Charles River Laboratories International, Inc. reported EPS of $2.43, beating estimates by 2.88%, and revenue of $1.00B, 0.42% above expectations.
The stock price moved down -5.71%, changed from $177.85 before the earnings release to $167.70 the day after.
The next earning report is scheduled for 17 de fev. de 2026.
Based on 15 analistas, Charles River Laboratories International, Inc. is expected to report EPS of $2.36 and revenue of $997.78M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio